Drug Profile
Tizanidine - Novartis
Alternative Names: AN 021A; AN-021; DS 103282 CH; DS-103282; Sirdalud; Ternelin; Tizanidine hydrochloride; ZanaflexLatest Information Update: 15 Jan 2019
Price :
$50
*
At a glance
- Originator Novartis
- Developer Acorda Therapeutics
- Class Antispastics; Benzothiazoles; Imidazolines; Muscle relaxants; Small molecules
- Mechanism of Action Alpha 2 adrenergic receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Muscle spasticity
- Discontinued Fibromyalgia; Migraine
Most Recent Events
- 08 Jan 2019 Shire has been acquired and merged into Takeda
- 16 Jul 2016 No recent reports of development identified for phase-I development in Muscle-spasticity(In adolescents, In children) in USA (PO, Capsule)
- 01 May 2014 Acorda Therapeutics completes a phase II QTc-interval trial in Healthy volunteers in USA (NCT01839279)